Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616094 · ClinicalTrials.gov registry record · NA
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 224
- Enrollment target
NCT02616094 is a NA study that has completed, run by Yale University. The registered enrollment target is 224 participants.
The verdict
NCT02616094, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 224 participants
- Enrollment target
Study Summary
Extending previous findings, and applying a novel multi-method translational approach, this project hypothesizes that there are alcohol-related neuroendocrine and neural changes observable in acute and protracted abstinence, and which can accurately classify future relapse and treatment outcome in separate alcohol dependent (AD) patient samples, thereby validating them as biomarkers of relapse, with potential clinical utility as prognostic markers in identifying and treating those most susceptible to relapse.
Interventions
- DEVICE Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
- DEVICE Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2015-11 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616094
The ClinicalTrials.gov registry entry for NCT02616094 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1 is the first listed.
NCT02616094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616094 about?
NCT02616094 is a clinical study titled "Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse". Extending previous findings, and applying a novel multi-method translational approach, this project hypothesizes that there are alcohol-related neuroendocrine and neural changes observable in acute and protracted abstinence, and which can accurately classify future relapse and treatment outcome in s...
What is the current status of trial NCT02616094?
This trial is currently completed. It is a NA study. The enrollment target is 224 participants. The study started on 2015-11. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02616094?
The interventions under investigation include: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1 (DEVICE), Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2 (DEVICE).
Who is sponsoring clinical trial NCT02616094?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.